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Abstract: Experimental evidence supports a protective role of estrogen in the brain. According 
to the fact that Alzheimer’s disease (AD) is more common in postmenopausal women, estrogen 
treatment has been proposed. However, there is no general consensus on the beneﬁ  cial effect of 
estrogen or selective estrogen receptor modulators in preventing or treating AD. It has to be said that 
several factors may markedly affect the efﬁ  cacy of the treatment. A few years ago, the seladin-1 gene 
(for selective Alzheimer’s disease indicator-1) has been isolated and found to be down-regulated 
in brain regions affected by AD. Seladin-1 has been found to be identical to the gene encoding the 
enzyme 3-beta-hydroxysterol delta-24-reductase, involved in the cholesterol biosynthetic pathway, 
which confers protection against β-amyloid-mediated toxicity and from oxidative stress, and is an 
effective inhibitor of caspase-3 activity, a key mediator of apoptosis. Interestingly, we found earlier 
that the expression of this gene is up-regulated by estrogen. Furthermore, our very recent data 
support the hypothesis that seladin-1 is a mediator of the neuroprotective effects of estrogen. This 
review will summarize the current knowledge regarding the neuroprotective effects of seladin-1 
and the relationship between this protein and estrogen.
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Introduction
Epidemiological data, together with experimental and clinical evidence, appear 
to support a neuroprotective role of estrogen, Accordingly, hormonal therapy in 
Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder in the 
elderly, has been suggested. However, there is no general consensus on this issue, 
which will be brieﬂ  y summarized in this review. A debated question concerns the 
factors that act as downstream mediators of estrogen receptor activation in the brain. 
The identiﬁ  cation of the seladin-1 gene and the ﬁ  nding that it protects the brain from 
toxic insults led us to hypothesize that this gene might represent the link between 
estrogen and neuroprotection. Seladin-1 was found to be identical to the gene encod-
ing the enzyme 3-beta-hydroxysterol delta-24-reductase involved in the cholesterol 
biosynthetic pathway. Cell cholesterol content appears to play an important role in 
protecting neuronal cells from toxic insults. This review will address the current 
knowledge on the neuroprotective effects of seladin-1 and the relationship between 
this protein and estrogen.
Estrogen receptor-mediated neuroprotection
This topic has been extensively reviewed by many authors and the literature will be 
brieﬂ  y summarized in this review. It is well known, based on in vitro evidence, that 
estrogen exerts neurotrophic and neuroprotective effects by stimulating the expression 
of neurotrophins and cell-survival factors, enhancing synaptic plasticity, and acting Neuropsychiatric Disease and Treatment 2008:4(4) 818
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as an antioxidant factor (Behl 2003; Maggi et al 2004; 
Turgeon et al 2006). In addition to the hypothalamus, 
which is the traditional site of estrogen action in the brain, 
both the estrogen receptor α (ERα) and β (ERβ) have been 
found in different brain areas such as the neocortex and the 
hippocampus, two areas highly involved in AD (Behl 2003). 
AD is the most prevalent form of late-life mental failure in 
humans (Selkoe 2001) and it has been calculated that every 
72 seconds someone in the United States develops this dis-
ease. However, unfortunately there is still no reliable way 
of preventing or curing this disease. Experimental evidence 
supports a favorable estrogen effect in neurons, in agreement 
with the knowledge that AD is more common in women and 
that decreased estrogen levels after menopause are a risk 
factor for the disease (Paganini-Hill and Henderson 1994). 
Thus, estrogen therapy has been considered a rationale option 
for the treatment of this disease. To date, despite the lack of 
general consensus, several studies indicated that estrogen 
treatment may decrease the risk or delay the onset of AD 
in postmenopausal women (Fillit 2002). Conversely, the 
data from the Women's Health Initiative Memory Study 
(WHIMS) trial showed that hormone replacement therapy 
(HRT) has no beneﬁ  t (Rapp et al 2003; Shumaker et al 
2003). However, it has to be remembered that different fac-
tors may determine the efﬁ  cacy of estrogen or HRT, such as 
age, the menopausal status, the route of administration and 
the dose, the starting cognitive function, and the presence of 
pre-existing risk factors (ie, smoking, apolipoprotein E geno-
type) (MacLusky 2004; Turgeon et al 2006). In particular, 
there seems to be a critical time for estrogen treatment. In fact, 
early and prolonged therapy has been found to produce the 
maximum beneﬁ  t in terms of reduced risk for AD (Resnick 
and Henderson 2002; Zandi et al 2002). In addition, estrogen 
therapy is not the same as HRT and the type of progestogen 
used may determine the outcome of the therapeutic interven-
tion (Schumacher et al 2007) (Figure 1).
With regard to the ER involved in neuroprotection, the 
observations from ERα (ERKO) and ERβ (βERKO) mice 
- Estrogen and 
progestin used
- Route of delivery 
- Dose
- Age of initiation
- Genetic background
-Baseline cognitive
function
Figure 1 Factors affecting the response of the brain to hormone replacement therapy.Neuropsychiatric Disease and Treatment 2008:4(4) 819
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suggest a critical role for ERα. In fact, whereas 17β-estradiol 
exerted a protective effect in the brain of ovariectomized 
βERKO mice, it did not in ERKO mice (Dubal et al 
2001). This ﬁ  nding appears in agreement with the reported 
decreased expression of ERα in hippocampal neurons of 
AD patients (Hu et al 2003). However, a possible role of 
ERβ in neuroprotection has been postulated, based on the 
evidence that βERKO mice undergo increased neuronal loss 
throughout life compared to wild-type controls (Wang et al 
2001). It has to be said that, in addition to classical nuclear 
ERs, more recent ﬁ  ndings suggest that the brain contains 
a plethora of ERs, such as ERγ and a variety of nuclear 
as well as cytoplasmic and plasma membrane receptors 
(Hawkins et al 2000; Toran-Allerand 2004; Vasudevan and 
Pfaff 2007; Arbogast 2008).
The neuroprotective role of the selective estrogen receptor 
modulators (SERMs) has been less extensively investigated. 
Nonetheless, a neuroprotective effect of tamoxifen and 
raloxifene has been observed (Dhandapani and Brann 2002) 
and a beneﬁ  cial role of tamoxifen and raloxifene against 
β-amyloid toxicity has been demonstrated in rat neurons 
(O’Neill et al 2004a, 2004b). There is increasing evidence 
that SERMs may also be neurotrophic, by increasing for 
instance synaptic density and stimulating neurite outgrowth 
(Dhandapani and Brann 2002). Data regarding the clinical 
use of SERMs in AD are very limited, so far. However, the 
Multiple Outcomes of Raloxifene Evaluation trial evaluated 
the cognitive function in more than 5000 women with osteo-
porosis assigned to receive raloxifene (60 mg or 120 mg) or 
placebo daily for three years. Compared to those taking pla-
cebo, women receiving 120 mg/day of raloxifene had a 33% 
lower risk of mild cognitive impairment and somewhat lower 
risks of Alzheimer’s disease and any cognitive impairment 
(Yaffe et al 2005).
In summary, the basic science strongly supports a 
neuroprotective role of estrogen/SERMs. Although there 
is no clear cut evidence yet that these molecules can 
decrease the risk or ameliorate the clinical course of AD, 
it is conceivable that there might be a proper space for a 
hormonal-based intervention in this disease. Undoubtedly, 
a more profound knowledge of the molecular mechanisms 
by which ERs activation determines neuroprotective effects 
may further support this conclusion.
The identiﬁ  cation
and characterization of seladin-1
The seladin-1 gene was first identified by Greeve and 
colleagues (2000), who used a differential mRNA display 
approach to identify genes that were differentially expressed 
in selective vulnerable brain regions in AD, such as the 
hippocampus, the amygdala, the inferior temporal cortex, and 
the enthorhinal cortex (Selkoe 2001). Among the 30 genes 
differentially expressed in AD vulnerable brain regions ver-
sus unaffected areas, Greeve and colleagues (2000) identiﬁ  ed 
a novel cDNA showing a markedly reduced expression in 
the inferior temporal cortex of AD patients compared to the 
frontal cortex, obtained shortly postmortem. Conversely, 
this cDNA was evenly expressed in the brain of unaffected 
individuals. This gene was named seladin-1 from selective 
Alzheimer’s disease indicator-1 and its full-length cDNA 
was cloned from a human brain cDNA library (GenBank 
accession number AF261758). The seladin-1 gene spans 46.4 
kb, maps to chromosome 1p31.1–p33, and comprises nine 
exons and eight introns; it encodes an open reading frame of 
516 amino acid residues. To localize the cellular distribution 
of seladin-1, human H4 neuroglioma cells were transfected 
with a seladin-1-green ﬂ  uorescent protein (GFP) fusion 
construct. Seladin-1 appeared to be mainly located in the 
endoplasmic reticulum and, although to a lesser extent, in 
the Golgi apparatus. A subsequent study demonstrated that 
the down-regulation of seladin-1 expression in vulnerable 
AD brain areas is paralleled by an increase in the amount of 
hyperhosphorylated tau, a protein component of neuroﬁ  bril-
lary tangles (Iivonen et al 2002). Apart the brain, seladin-1 
mRNA has been also detected in many different human 
organs and the highest levels of expression have been found 
in the adrenal gland, the liver, the lung and the prostate.
With regard to its biological effects, seladin-1 was 
found to confer resistance against β-amyloid and oxidative 
stress-induced apoptosis and to effectively inhibit the 
activation of caspase-3, a key mediator of the apoptotic 
process. However, another study indicated that this multi-
faced protein may have a more complex role in cell apoptosis. 
In fact, following oncogenic and oxidative stress, seladin-1 
was found to bind P53 amino terminus domain and to displace 
E3 ubiquitin ligase Mdm2 from P53, thus resulting in P53 
accumulation (Wu et al 2004).
Seladin-1 was found to have also an enzymatic activity 
involved in cholesterol biosynthesis, which was found to 
be markedly reduced in desmosterolosis, a rare autosomal 
recessive disorder characterized by multiple congenital 
anomalies (Fitzpatrick et al 1998). In fact, patients with des-
mosterolosis have elevated plasma levels of the cholesterol 
precursor desmosterol and this abnormality suggested a deﬁ  -
ciency of the enzyme 3-beta-hydroxysterol delta-24-reductase 
(DHCR24), which catalyzes the reduction of the ∆24 double Neuropsychiatric Disease and Treatment 2008:4(4) 820
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bond in desmosterol to produce cholesterol. Waterham 
and colleagues (2001) were able to identify the human 
DHCR24 cDNA, which appeared identical to seladin-1. 
DHCR24 activity was conﬁ  rmed in vitro by enzymatic assay 
following heterologous expression of the DHCR24 cDNA 
in Saccharomyces cerevisiae. Conversely, in constructs 
containing mutant DHCR24 alleles from patients with desmo-
sterolosis the conversion from desmosterol into cholesterol 
was nil or markedly reduced.
Desmosterolosis belongs to a group of several inherited 
disorders, linked to enzyme defects in the cholesterol 
biosynthetic pathway at the post-squalene level, which 
have been described in recent years (Herman 2003). These 
genetic diseases are characterized by major developmental 
malformations and in most cases determine severe neuro-
psycological alterations, suggesting an important role of 
cholesterol in brain homeostasis. The role of cholesterol in 
facilitating the onset and progression of AD is a debated and 
unsolved question. In fact, on one hand cholesterol may be 
viewed as a toxic factor. It has been reported that elevated 
cholesterol levels increase β-amyloid formation in in vitro 
systems and in most animal models of AD (Yanagisawa 2002; 
Puglielli et al 2003). The identiﬁ  cation of the ε4 allelic 
variant of the apolipoprotein E as a major genetic risk fac-
tor for AD is also consistent with a role of cholesterol in the 
pathogenesis of this disease. Accordingly, epidemiological 
studies suggested that statin therapy may provide protection 
against AD, although the clinical beneﬁ  t of statins might be 
also due to their cholesterol-independent effects on cerebral 
circulation and inﬂ  ammation (Reiss et al 2004). This hypoth-
esis appears to be substantiated by the fact that the majority 
of the commercially available statins does not cross the 
blood–brain barrier. On the other hand, it has to be considered 
that the central nervous system (CNS) is a very unique organ 
with regard to cholesterol metabolism: in fact, although the 
CNS accounts for only 2% of the entire body mass, it contains 
about 25% of the total amount of unesteriﬁ  ed cholesterol in 
the entire body. In addition, most of the CNS cholesterol is 
produced via local de novo synthesis. Keeping this in mind, 
it is not surprising that several studies pointed out the fact 
that the intracellular content of cholesterol, particularly the 
amount contained in the cell membrane, should be addressed 
much more than the plasma levels (Yanagisawa 2002). In this 
new scenario, an appropriate amount of membrane choles-
terol would create a barrier against toxic insults, whereas a 
cholesterol-depleted membrane would ease the interaction 
with toxic factors such as β-amyloid, which may generate for 
instance an anomalous number of calcium channels leading 
to the accumulation of toxic levels of calcium (Arispe and 
Doh 2002). In addition, in membranes from AD patients 
or in rodent hippocampal neurons with a moderate reduc-
tion of membrane cholesterol the interaction between the 
amyloidogenic enzyme β-secretase and amyloid precursor 
protein (APP) appeared to be facilitated, thus leading to ele-
vated production of β-amyloid (Abad-Rodriguez et al 2004). 
These results suggest that loss of neuronal membrane choles-
terol contributes both to increased membrane interaction with 
β-amyloid and to excessive amyloidogenesis in AD. Thus, the 
reduced expression of seladin-1 in AD vulnerable regions is 
in keeping with the “membrane integrity” theory.
Mice with a targeted disruption of the DHCR24 gene 
have been generated (Wechsler et al 2003). As expected, 
plasma and tissues of DHCR24-/- mice contained virtually 
no cholesterol, whereas desmosterol accumulation was 
observed. These animals were around 25% smaller in size 
than DHCR24+/+ and DHCR24+/- littermates at birth. In con-
trast to initial observations, it was subsequently demonstrated 
that these animals show a lethal dermopathy at birth and 
die within a few hours (Mirza et al 2006). This ﬁ  nding is in 
agreement with the severe phenotype observed in humans 
affected by desmosterolosis.
Seladin-1 as a new  effector
of ER-mediated neuroprotection
As mentioned previously, there is experimental evidence 
that estrogen and SERMs may confer neuroprotection. 
However, in most of the studies, that have been performed 
so far, animal models have been used. In other cases human 
cells, yet transformed or of neoplastic origin, have been 
used. Recently, we addressed the neuroprotective effects 
of estrogen/SERMs using a unique human cell model, ie, 
GnRH-secreting neuroblast long-term cell cultures from 
human fetal (8–12 weeks of gestational age) olfactory 
epithelium. These fetal neuroepithelial cells (FNC) were 
established, cloned and propagated previously by Vannelli 
and colleagues (1995) at the Department of Anatomy, 
Histology, and Forensic Medicine of the University of 
Florence, Italy. They show unique features, because they 
express both neuronal and olfactory markers that are typical 
of maturing olfactory receptor neurons (Vannelli et al 1995). 
FNC cells are electrically excitable and following exposure 
to a number of different aromatic chemicals show a speciﬁ  c 
increase in intracellular cAMP, indicating some degree of 
functional maturity. Thus, FNC cells appear to originate 
from the stem cell compartment that generates mature 
olfactory receptor neurons. In addition,  they express both Neuropsychiatric Disease and Treatment 2008:4(4) 821
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ERα and β (Barni  et al 1999). Therefore, they represented 
a suitable human in vitro model, that could be of help in 
i) providing further information on the role of estrogen in 
neurons, and in ii) answering the question whether seladin-1 
might be an effector of ERs activation.
Our ﬁ  ndings conﬁ  rmed the protective role of estrogen/
SERMs in the brain. In fact, we observed that, whereas 
in the absence of estrogen pre-incubation β-amyloid 
(10 and 100 nM) and H2O2 (200 µM) significantly 
reduced cell viability, the pre-treatment with 17β-estradiol 
(100  pM–100 nM) effectively counteracted β-amyloid- or 
oxidative stress-induced toxicity (Benvenuti et al 2005). 
In agreement with estrogen, also the SERM tamoxifen 
(100 pM–100 nM) effectively protected FNC cells from the 
toxic effects of β-amyloid, whereas partially different results 
were observed using raloxifene. In fact, cell viability after 
exposure to β-amyloid was preserved at low concentrations 
of raloxifene (100 pM and 1 nM). Conversely, 10 and 
100 nM did not exert protective effects (Figure 2). In addi-
tion, we demonstrated that the protective action of estrogen 
in FNC cells was associated to a counteracting effect against 
β-amyloid-induced apoptosis, as demonstrated by the strong 
inhibition of the activation of caspase-3.
Finally, in order to answer the question whether 
estrogen and/or SERMs have an effect on seladin-1 expres-
sion, we evaluated the expression of seladin-1 mRNA in 
FNC cells, treated or not with 17β-estradiol, tamoxifen 
or raloxifene, by quantitative real-time RT-PCR based on 
TaqMan technologies. We found that FNC cells consti-
tutively express seladin-1 (112 ± 2.26 fg/µg total RNA, 
mean ± SE). Noticeably, 17β-estradiol (10 pM–100 nM) 
signiﬁ  cantly increased the amount of seladin-1 mRNA. 
1 nM tamoxifen or raloxifene determined a similar increase 
of seladin-1 mRNA, compared to an equal concentration of 
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17β-estradiol. However, higher concentrations of raloxifene 
(10–100 nM) determined a marked reduction of seladin-1 
expression, in keeping with the observed lack of a neuropro-
tective effect at these concentrations (Figure 3). The effect 
of a selective ERα (propylpyrazole-triol, PPT) or a selective 
ERβ (diarylpropionitrile, DPN) agonist was also tested. 
We found that PPT determined a signiﬁ  cant increase of the 
amount of seladin-1 mRNA at a concentration (10 nM) which 
has been reported to induce evident transcriptional activity 
(Harrington et al 2003), whereas DPN produced a weaker 
effect. These additional ﬁ  ndings suggested a predominant 
role of ERα in mediating the stimulatory effect of estrogen 
on seladin-1 expression. In conclusion, this study led us 
to hypothesize that seladin-1 might be a mediator of the 
neuroprotective effects of estrogen/SERMs. In particular, 
the parallelism between the concentrations of raloxifene 
that conferred neuroprotection on one hand, and stimulated 
seladin-1 expression on the other hand, was highly predictive 
that this was true.
This hypothesis was supported by very recent 
additional ﬁ  ndings. In fact, we demonstrated that, upon 
silencing seladin-1 expression by small interfering RNA 
methodology, the protective effect against β-amyloid 
and oxidative stress toxicity exerted by 17β-estradiol was 
lost. Furthermore, a computer-assisted analysis revealed 
the presence of half-palindromic estrogen responsive 
elements (EREs) upstream the coding region of the 
seladin-1 gene. A region spanning around 1500 bp was 
cloned in a luciferase reporter vector, which was transiently 
co-transfected with the estrogen receptor α in CHO cells. 
The exposure to 17β-estradiol, as well as to raloxifene and 
tamoxifen increased luciferase activity, thus suggesting 
a functional role for the half EREs of the seladin-1 gene 
(Luciani et al 2008). Admittedly, these data provide a direct 
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demonstration that seladin-1 is a fundamental mediator of 
the neuroprotective effects of estrogen.
Conclusions
ER-mediated neuroprotection has been assessed by a number 
of studies and justiﬁ  es the attempts that have been proposed 
to prevent of treat AD with estrogen or SERMs. The partially 
disappointing results from previous clinical trials may have 
been determined by several confounding factors, such as the 
rather advanced age of the patients, the cognitive function 
at baseline, the presence of pre-existing risk factors and the 
progestogen used. Our data reinforce the role of estrogen 
as a protective factor for the brain and address seladin-1 as 
a mediator of this effect. Thus, we feel that further trials 
involving estrogen or SERMs in neuroprotection may be 
encouraged, provided that the patients are carefully selected 
and the treatment regimen is appropriately chosen.
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